ArticleWorld psychiatry : official journal of the World Psychiatric Association (WPA)2024
Effects of cannabidiol on symptoms in people at clinical high risk for psychosis.
Article in World psychiatry : official journal of the World Psychiatric Association (WPA), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Does cannabidiol reduce the adverse effects of cannabis in schizophrenia? A randomised, double-blind, cross-over trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Trial
- Brain-enriched extracellular vesicle microRNAs could help to predict onset of psychosis in people at clinical high risk.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2026Article
- Real-world comprehensive care of people living with schizophrenia: recommendations across different settings and clinical stages.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2026Article
- Gray Matter Volume Loss in Parkinson's Disease Psychosis and Cannabinoid Receptor Gene Expression in the Brain.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- Persistent negative symptoms in the EULAST cohort: impact on functional outcome.Schizophrenia (Heidelberg, Germany) · 2026Article
- Acceptability of cannabidiol as a treatment for people at clinical high risk for psychosis.Frontiers in psychiatry · 2026Article
- Effects of palmitoylethanolamide in clinical high-risk for psychosis: A nonrandomized open-label trial.Brain, behavior, & immunity - health · 2025Article
- Effectiveness of a social cognition remediation intervention for patients with schizophrenia: a randomized-controlled study.Annals of general psychiatry · 2024Article
- Green rush and red warnings: Retrospective chart review of adverse events of interactions between cannabinoids and psychotropic drugs.Frontiers in pharmacology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.